300 related articles for article (PubMed ID: 16608533)
1. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.
Han W; Han MR; Kang JJ; Bae JY; Lee JH; Bae YJ; Lee JE; Shin HJ; Hwang KT; Hwang SE; Kim SW; Noh DY
BMC Cancer; 2006 Apr; 6():92. PubMed ID: 16608533
[TBL] [Abstract][Full Text] [Related]
2. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
3. Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with high estrogen receptor values?
Floiras JL; Hacene K; Turpin F; Spyratos F
Int J Biol Markers; 2000; 15(2):135-8. PubMed ID: 10883886
[TBL] [Abstract][Full Text] [Related]
4. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
5. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
[TBL] [Abstract][Full Text] [Related]
6. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
Novoa Vargas A; Font López KC; Amador DD
Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
[TBL] [Abstract][Full Text] [Related]
7. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Di Lauro L; Vici P; Del Medico P; Laudadio L; Tomao S; Giannarelli D; Pizzuti L; Sergi D; Barba M; Maugeri-Saccà M
Breast Cancer Res Treat; 2013 Aug; 141(1):119-23. PubMed ID: 23982884
[TBL] [Abstract][Full Text] [Related]
8. IGF-II mRNA expression in breast cancer: predictive value and relationship to other prognostic factors.
Fiore E; Campani D; Muller I; Belardi V; Giustarini E; Rossi G; Pinchera A; Giani C
Int J Biol Markers; 2010; 25(3):150-6. PubMed ID: 20677165
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Fisher B; Dignam J; Wolmark N; DeCillis A; Emir B; Wickerham DL; Bryant J; Dimitrov NV; Abramson N; Atkins JN; Shibata H; Deschenes L; Margolese RG
J Natl Cancer Inst; 1997 Nov; 89(22):1673-82. PubMed ID: 9390536
[TBL] [Abstract][Full Text] [Related]
10. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
11. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes.
Loo LW; Grove DI; Williams EM; Neal CL; Cousens LA; Schubert EL; Holcomb IN; Massa HF; Glogovac J; Li CI; Malone KE; Daling JR; Delrow JJ; Trask BJ; Hsu L; Porter PL
Cancer Res; 2004 Dec; 64(23):8541-9. PubMed ID: 15574760
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
14. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
[TBL] [Abstract][Full Text] [Related]
15. [Synchronous bilateral breast cancer in a male].
García-Mejido JA; Delgado-Jiménez C; Gutiérrez-Palomino L; Sánchez-Sevilla M; Iglesias-Bravo E; Caballero-Fernández V
Cir Cir; 2013; 81(3):225-7. PubMed ID: 23769252
[TBL] [Abstract][Full Text] [Related]
16. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
17. Thyroid cancer presenting as a PET incidentaloma in a patient with concomitant breast cancer metastases to the thyroid.
Leboeuf R; Bénard F; Langlois MF
Clin Nucl Med; 2006 Jul; 31(7):382-5. PubMed ID: 16785803
[TBL] [Abstract][Full Text] [Related]
18. [Adjuvant treatment of operable breast cancer].
Khosravi Shahi P; Izarzugaza Perón Y; Encinas García S; Díaz Muñoz de la Espada VM; Pérez Manga G
An Med Interna; 2008 Jan; 25(1):36-40. PubMed ID: 18377195
[TBL] [Abstract][Full Text] [Related]
19. Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer.
Di Leo A; Buyse M
J Clin Oncol; 2002 Apr; 20(7):1954-5. PubMed ID: 11919262
[No Abstract] [Full Text] [Related]
20. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG)
J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
